Ming Yang

Dr. Ming Yang


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2024 in Life Sciences
Verified
Journal Article
Closed access
JWJing Wang
Jing Wang
MHMei He
Mei He
MYMing Yang
Ming Yang
XAXiaopeng Ai
Xiaopeng Ai

15 November 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
JWJing Wang
Jing Wang
YHYaqin Hou
Yaqin Hou
LMLifeng Mu
Lifeng Mu
MYMing Yang
Ming Yang
XAXiaopeng Ai
Xiaopeng Ai

6 July 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
PYPeiling Yu
Peiling Yu
JWJing Wang
Jing Wang
JLJia Liu
Jia Liu
YZYue Zhou
Yue Zhou
FLFei Luo
Fei Luo
XAXiaopeng Ai
Xiaopeng Ai

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YZYue Zhou
Yue Zhou
MHMei He
Mei He
RLRui Li
Rui Li
YPYuan Peng
Yuan Peng
FLFeng Li
Feng Li
MYMing Yang
Ming Yang
Objective. Bevacizumab was currently available for nonsquamous non‐small‐cell lung cancer (NSqNSCLC) patients and has been studied in several randomized controlled trials (RCTs) for treatment of these patients. This meta‐analysis summarizes the most up‐to‐date evidences regarding the effects and adverse reactions of bevacizumab in the treatment of NSqNSCLC patients. Methods. The authors searched for RCTs from electronic database including PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. Experimental arm was defined as the bevacizumab‐containing group and the control arm as the bevacizumab‐free group. Data of objective response rate (ORR), disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), and adverse reactions were synthetically extracted. A protocol for this meta‐analysis has been registered on PROSPERO (http://www.crd.york.ac.uk/prospero). Results. Ten RCTs that involved a total of 3134 patients were included. The experimental group was associated with significant superior ORR (RR 1.63, 95% CI 1.24 to 2.14, P < 0.001), OS (HR 0.90, 95% CI 0.82 to 0.99, P < 0.001), and prolonged PFS (HR 0.68, 95% CI 0.62 to 0.74, P < 0.001) compared to the control. No significant difference was observed regarding DCR (RR 1.13, 95% CI 0.99 to 1.30, P = 0.08). The experimental group showed higher rate of hypertension (RR 6.91, 95% CI 4.62 to 10.35, P < 0.00001) and hemorrhagic events (RR 3.07, 95% CI 1.78 to 5.30, P < 0.0001) than the control group. The experimental group showed lower rate of anemia (RR 0.72, 95% CI 0.55 to 0.96, P = 0.02) than the control group. No significant difference was observed regarding treatment‐related adverse event grade 3‐5 (TRAE3‐5) (RR 1.23, 95% CI 0.99 to 1.53, P = 0.06), thrombocytopenia (RR 1.11, 95% CI 0.92 to 1.33, P = 0.29), and neutropenia (RR 1.11, 95% CI 0.88 to 1.40, P = 0.36). Conclusion. This meta‐analysis showed that bevacizumab could increase ORR, OS, and prolonged PFS for treatment of NSqNSCLC patients. However, no significant improvement in DCR was observed and bevacizumab could increase the rate of hypertension and hemorrhagic events. Bevacizumab was an acceptable option for NSqNSCLC patients. This trial is registered with PROSPERO registration number: CRD42021226790.

23 November 2024 in Current Microbiology
Verified
Journal Article
Closed access
PDF file
YZYue Zhou
Yue Zhou
JCJingyang Chang
Jingyang Chang
FLFeng Li
Feng Li
MHMei He
Mei He
RLRui Li
Rui Li
MYMing Yang
Ming Yang

7 May 2022 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
LCLin Cheng
Lin Cheng
PYPu Yao
Pu Yao
BWBangbi Weng
Bangbi Weng
MYMing Yang
Ming Yang
QWQian Wang
Qian Wang